Hims & Hers Health
HIMS
shares were down more than 34.63% in Monday trading, while Novo Nordisk
NVO stock was down over 5% after Novo Nordisk said it has halted its collaboration with Hims & Hers on the sale of weight loss drugs, including Wegovy.
The two companies launched a collaboration in April to bundle Wegovy through Hims & Hers' telehealth platform.
Novo Nordisk said direct access to the drug would no longer be available through Hims & Hers Health because the company "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk."
This stock failed to catch a bid despite the equity markets strong.
HIMS
shares were down more than 34.63% in Monday trading, while Novo Nordisk
NVO stock was down over 5% after Novo Nordisk said it has halted its collaboration with Hims & Hers on the sale of weight loss drugs, including Wegovy.
The two companies launched a collaboration in April to bundle Wegovy through Hims & Hers' telehealth platform.
Novo Nordisk said direct access to the drug would no longer be available through Hims & Hers Health because the company "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk."
This stock failed to catch a bid despite the equity markets strong.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.